Literature DB >> 8866833

Inducing properties of rifabutin, and effects on the pharmacokinetics and metabolism of concomitant drugs.

M S Benedetti1.   

Abstract

Rifabutin, a rifamycin derivative like rifampicin, has been registered for the treatment of pulmonary tuberculosis and for the prophylaxis and treatment of MAC in patients with AIDS. Rifabutin induces cytochrome P-450 3A4. The effect of rifabutin on the pharmacokinetics and metabolism of drugs administered concomitantly to humans (isoniazid, ethambutol, zidovudine, didanosine, delavirdine, fluconazole, itraconazole, methadone, clarithromycin, theophylline and cyclosporin) has been reviewed.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8866833     DOI： 10.1016/s1043-6618(05)80021-0

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN： 1043-6618            Impact factor:   7.658


  7 in total

Review 1.  Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias.

Authors:  Stig Thunell; Erik Pomp; Atle Brun
Journal:  Br J Clin Pharmacol       Date:  2007-06-19       Impact factor: 4.335

2.  Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin.

Authors:  X G Liu; P K Narang; R C Li
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

3.  Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection.

Authors:  J W C Alffenaar; W A Nienhuis; F de Velde; A T Zuur; A M A Wessels; D Almeida; J Grosset; O Adjei; D R A Uges; T S van der Werf
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

4.  Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients.

Authors:  Elinore F McCance-Katz; David E Moody; Sudha Prathikanti; Gerald Friedland; Petrie M Rainey
Journal:  Drug Alcohol Depend       Date:  2011-05-19       Impact factor: 4.492

5.  Tuberculosis and histoplasmosis co-infection in AIDS patients.

Authors:  Carlos A Agudelo; Carlos A Restrepo; Diego A Molina; Angela M Tobón; Carol A Kauffman; Carolina Murillo; Angela Restrepo
Journal:  Am J Trop Med Hyg       Date:  2012-11-05       Impact factor: 2.345

Review 6.  Treatment of tuberculous infection and disease in children: the North American perspective.

Authors:  C D Stowe; R F Jacobs
Journal:  Paediatr Drugs       Date:  1999 Oct-Dec       Impact factor: 3.930

7.  Concomitant disseminated histoplasmosis and disseminated tuberculosis after tumor necrosis factor inhibitor treatment: a case report.

Authors:  Juan E Muñoz-Oca; Martha L Villarreal Morales; Aracelis Nieves-Rodriguez; Lemuel Martínez-Bonilla
Journal:  BMC Infect Dis       Date:  2017-01-13       Impact factor: 3.090
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.